Breadcrumb

Asset Publisher

null Hospital San Cecilio group (Granada)

Hospital Universitario San Cecilio (Granada)

Description

Members
Publications

The Hospital San Cecilio group was started in 2000 and joined RIS in 2004 as a clinical associate group and upgraded to a core group in 2012. The group is actively involved in research on viral resistance in Spain in the field of HIV and hepatitis C. At the national level, the group co-coordinates the WP of resistance & subtypes of the RIS, actively participates in GEHEP (Spanish Group for the Study of Hepatitis-SEIMC), is leading clinical research on human papillomaviruses, and is also involved in research on microbiome and metagenomics. The group actively participates in international collaborations related to resistance to antivirals and hepatitis C (CHAIN, ART collaboration, PLATO II, Coronet, SPREAD, EucoHIV, Eurocoord, CAPRE, HEPC-Care, Shared). 

    The areas of research in which the group is currently involved are:

  1. Resistance to antiretrovirals: the group leads the research on transmitted drug resistance in CoRIS. At present research is focused on TDR to first line drugs. The group is conducting the surveillance programme on TDR to integrase inhibitors.
  2. Resistance to direct acting antiviral drugs (DAAs) against hepatitis C virus: the group is leading DAA resistance studies in Spain, both at baseline and failures, giving service to many groups from RIS. The group is actively involved in characterising reinfection events, and how to apply phylogenetic analysis tools for this topic, and also to evaluate the introduction of HCV in Spain, its spread across the country, and from Spain to other parts of the world.
  3. Human papillomavirus in HIV patients: the group has a leadership in the evaluation of the efficacy of vaccination against HPV in HIV patients and on clinical and epidemiological studies of HPV in HIV positive patients
  4. Microbiome analysis: the group has numerous collaborations on microbiome analysis related with probiotics, periodontal diseases, digestive diseases, and other areas (trasplant, basic research)

Related Assets

Members

Federico García
Federico García
Marta Álvarez
Marta Álvarez
Natalia Chueca
Natalia Chueca
Carmen Hidalgo
Carmen Hidalgo
María Dolores Merida
María Dolores Merida
Antonio Sanchez
Antonio Sanchez
David Vinuesa
David Vinuesa

Related Assets

Related Assets

Publications

  • Sample pooling for SARS-CoV-2 RT-PCR screening.
    de Salazar A, Aguilera A, Trastoy R, Fuentes A, Alados JC, Causse M, Galán JC, Moreno A, Trigo M, Pérez-Ruiz M, Roldán C, Pena MJ, Bernal S, Serrano-Conde E, Barbeito G, Torres E, Riazzo C, Cortes-Cuevas JL, Chueca N, Coira A, Sanchez-Calvo JM, Marfil E, Becerra F, Gude MJ, Pallarés Á, Pérez Del Molino ML, García F.  Clin Microbiol Infect. 2020 Sep 10:S1198-743X(20)30537-1. doi: 10.1016/j.cmi.2020.09.008. 
  • Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
    Adolfo DE SALAZAR1†, Julia DIETZ2†, Velia Chiara DI MAIO3†, Johannes VERMEHREN2, Stefania PAOLUCCI4, Beat MÜLLHAUPT5, Nicola COPPOLA6, Joaquín CABEZAS7, Rudolf E. STAUBER8, Massimo PUOTI9, Juan Ignacio ARENAS RUIZ TAPIADOR10, Christiana GRAF2, Marianna ARAGRI3, Miguel JIMENEZ11, Annapaola CALLEGARO12, Juan Manuel PASCASIO ACEVEDO13, Manuel Alberto MACIAS RODRIGUEZ14, Jose Miguel ROSALES ZABAL15, Valeria MICHELI16, Miguel GARCIA DELTORO17, Francisco TÉLLEZ18, Federico GARCÍA1‡*, Christoph SARRAZIN2,19‡ and Francesca CECCHERINI-SILBERSTEIN3‡.  Journal of Antimicrobial Chemotherapy, 2020. Doi: 10.1093/jac/dkaa304 . 1º DECIL/LIDERADO (Corresponding author) 
  • The algorithm used for the interpretation of Doravirine transmitted drug resistance strongly influences clinical practice and guidelines recommendations.
    Carlos GUERRERO-BELTRÁN1#, Javier MARTÍNEZ-SANZ2#, Marta ÁLVAREz1 Julián OLALLA3, Mónica GARCÍA-ÁLVAREZ4, Jose Antonio IRIBARREN5, Mar MASIÁ6, Marta MONTERO7, Silvia GARCÍA-BUJALANCE8, José Ramón BLANCO9, María RIVERO10, Lucio Jesús GARCÍA-FRAILE11, Núria ESPINOSA12, Carmen RODRÍGUEZ13, Antonio AGUILERA14, María Carmen VIDAL-AMPURDANES15, Marina MARTÍNEZ16, Asunción IBORRA17, Arkaitz IMAZ18, Juan Luis GÓMEZ-SIRVENT19, Joaquim PERAIRE20, Joaquín PORTILLA21, Estrella CABALLERO22, Belén ALEJOS23 Federico GARCÍA1*# and Santiago MORENO2# on behalf of CoRIS.  Journal of Antimicrobial Chemotherapy, 2020. 75(5):1294-1300. Article Doi: 10.1093/jac/dkaa009. 1º DECIL/LIDERADO (Corresponding author) 
  • Cross country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.
    Vrancken B, Cuypers L, Pérez AB, Chueca N, Anton-Basantas J, de la Iglesia A, Fuentes J, Pineda JA, Téllez F, Bernal E, Rincón P, Von Wichman MA, Fuentes A,Vera F, Rivero-Juárez A, Jiménez M, Vandamme AM, García F.  J Hepatol. 2019 Dec;71(6):1270-1272. Doi: 10.1016/j.jhep.2019.08.010. 1º DECIL/LIDERADO (ultimo) 
  • High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB, Chueca N, García-Deltoro M, Martínez-Sapiña AM, Lara-Pérez MM, García-Bujalance S, Aldámiz-Echevarría T, Vera-Méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-Arboledas JC, Poyato A, Téllez F, Rivero-Juárez A, Merino D, Vivancos-Gallego MJ, Rosales-Zábal JM, García F; GEHEP- 004 Study Group.  J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4. PubMed PMID: 31279901. 1º DECIL/LIDERADO (ultimo) 
  • Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice;
    Alvarez M(1), Casas P(1), de Salazar A(1), Chueca N(1), Guerrero-Beltran C(1), Rodríguez C(2), Imaz A(3), Espinosa N(4), García-Bujalance S(5), Pérez-Elías MJ(6), García-Alvarez M(7), Iribarren JA(8), Santos J(9), Dalmau D(10), Aguilera A(11), Vinuesa D(12), Gutiérrez F(13), Piérola B(14), Molina JM(15), Peraire J(16), Portilla I(17), Gómez-Sirvent JL(18), Olalla J(19), Galera C(20), Blanco JR(21), Riera M(22), García-Fraile L(23), Navarro G(24), Curran A(25), Poveda E(26), García F(1); CoRIS.  Journal of Antimicrobial Chemotherapy, 2019. 2019 Jun 1;74(6):1693-1700. Article Doi: 10.1093/jac/dkz067. 1º DECIL/LIDERADO (ultimo) 
  • Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain.
    Pérez Ana Belen, Vrancken Bram, Chueca Natalia, Aguilera Antonio, Reina Gabriel, García-del Toro Miguel, Vera Francisco, Von Wichman Miguel Angel, Arenas Juan Ignacio, Téllez Francisco, Pineda Juan A, Omar Mohamed, Bernal Enrique, Rivero-Juárez Antonio, Fernández-Fuertes Elisa, de la Iglesia Alberto, Pascasio Juan Manuel, Lemey Philippe, Garcia Féderico, Cuypers Lize.  Euro Surveill. 2019;24(9):pii=1800227. https://doi.org/10.2807/1560-7917.ES.2019.24.9.1800227 1º DECIL/LIDERADO (Corresponding author) 
  • Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain. 
    Pérez-Parra S(1), Álvarez M(1), Fernandez-Caballero JA(1), Pérez AB(1), Santos J(2), Bisbal O(3), Aguilera A(4), Rivero M(5), García-Fraile L(6), García F(1)  The Journal of antimicrobial chemotherapy, 2018 Apr 1;73(4):1031-1038 1º DECIL/LIDERADO (ultimo) 
  • One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents. 
    Ruiz A, Cerdó T, Jáuregui R, Pieper DH, Marcos A, Clemente A, García F, Margolles A, Ferrer M, Campoy C, Suárez A.  Environ Microbiol. 2017 Apr;19(4):1536-1551. doi: 10.1111/1462-2920.13713. 
  • High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach. 
    Pérez-Parra S, Chueca N, Álvarez M, Pasquau J, Omar M, Collado A, Vinuesa D, Lozano AB, Yebra G, García F.  PLoS One. 2017 Oct 30;12(10):e0186928. doi: 10.1371/journal.pone.0186928. eCollection 2017. 

Related Assets